Used for the treatment of locally advanced or metastatic, hormone-dependent prostate cancer
Hyderabad, India – December 07, 2012 – Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) today announced that it has launched PamorelinÒ LA in India on December 03, 2012, under an exclusive marketing and sales agreement with Debiopharm GroupTM, Switzerland. PamorelinÒ LA is used for the treatment of locally advanced or metastatic, hormone-dependent prostate cancer.
PamorelinÒ LA will be imported in bulk from Debio Recherche Pharmaceutique (Debio R.P.). It will be made available primarily to urologists and oncologists across India.
This press release includes forward-looking statements, as defined in the U.S. Private Securities Litigation Reform Act of 1995. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.
About Pamorelin® LA (active ingredient : triptorelin)
Triptorelin is an agonist analogue of the natural gonadotropin-
About Dr. Reddy’s
Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars, differentiated formulations and NCEs. Therapeutic focus is on gastro-intestinal, cardiovascular, diabetology, oncology, pain management, anti-infective and pediatrics. Major markets include India, USA, Russia and CIS, Germany, UK, Venezuela, S. Africa and Romania.
For more information, log on to: www.drreddys.com
About Debiopharm Group™
Debiopharm Group™ (Debiopharm)
For more information on Debiopharm Group™, please visit: www.debiopharm.com.
About Debio R.P.
Debio Recherche Pharmaceutique (Debio R.P.), based in Martigny (Switzerland)
Dr. Reddy’s Laboratories
email@example.com / +91-40-49002445
Investors and Financial Analysts:
firstname.lastname@example.org / +91-40-66834297
Milan Kalawadia (USA)
email@example.com / +1 908-203-4931
Debiopharm S.A. Contact
Director Corporate Affairs & communication
Tel.: +41 (0)21 321 01 11
Fax: +41 (0)21 321 01 69
Additional Media Contacts
Tel: +44 (0)20 7379 5151
In New York
Russo Partners, LLC
Martina Schwarzkopf, Ph.D.
Tel: +1 212-845-4292
Fax: +1 212-845-4260